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A B S T R A C T
Multiple classes of agent with distinct mechanisms of action are now available for the treatment of patients with
relapsed and/or refractory multiple myeloma (RRMM), including immunomodulatory agents, proteasome in-
hibitors, histone deacetylase inhibitors and monoclonal antibodies. Additionally, several diﬀerent drugs may be
available within each agent class, each with their own speciﬁc eﬃcacy and safety proﬁle. This expansion of the
treatment landscape has dramatically improved outcomes for patients. However, as the treatment options for
RRMM become more complex, choosing the class of agent or combination of agents to use in the relapsed setting
becomes increasingly challenging. Furthermore, treatment options for speciﬁc patient populations such as the
elderly, those with high-risk cytogenetic abnormalities and those with refractory disease are yet to be deﬁned in
the current treatment landscape. When choosing an appropriate treatment approach, physicians must consider
multiple criteria including both patient-related and disease-related factors. The aim should be to provide patient-
speciﬁc treatment in order to gain a clinical beneﬁt while minimizing toxicity. This review provides an overview
of the mechanism of action and eﬃcacy and safety proﬁles of each class of agent and of treatment regimens that
combine diﬀerent classes of agent, with a special focus on treating speciﬁc patient populations.
1. Introduction
Multiple myeloma (MM) is characterized by a relapsing disease
course. Despite signiﬁcant improvements in patient outcomes following
the introduction of immunomodulatory drugs (IMiDs) and proteasome
inhibitors (PIs) in the ﬁrst-line setting (Kumar et al., 2008), most pa-
tients eventually relapse, and the management of relapsed and/or re-
fractory MM (RRMM) remains a challenge (Laubach et al., 2016). The
treatment landscape for patients with RRMM is rapidly changing fol-
lowing the recent approval of three drugs belonging to two novel
classes of agent in this setting: a histone deacetylase (HDAC) inhibitor
(HDI), panobinostat (Farydak, 2016a; Farydak, 2016b), and two
monoclonal antibodies (mAbs), daratumumab and elotuzumab (Squibb,
2015; Squibb, 2016; Darzalex, 2015; Darzalex, 2016). Furthermore, the
addition of the second-generation IMiDs lenalidomide and pomalido-
mide (Celgene Corporation POMALYST, 2016; Celgene Europe Ltd.,
2016a; Celgene Corporation Revlimid, 2013; Celgene Europe Ltd.,
2016b) and the second-generation PIs carﬁlzomib and ixazomib
(Kyprolis, 2015; Kyprolis, 2016; Millennium Pharmaceuticals Ninlaro,
2015; Takeda Pharma Nilaro, 2016) provides additional within-class
treatment options for patients with RRMM. With multiple classes of
agent now available, each with diﬀering mechanisms of action and
eﬃcacy and safety proﬁles, it can be diﬃcult for physicians to decide
upon the most appropriate agent to use. In the relapsed setting, treat-
ment choice is additionally inﬂuenced by a number of patient- and
disease-related factors such as age, cytogenetics, pre-existing toxicities,
aggressiveness of relapse, previous therapy, response to previous
therapy and number of previous therapy lines (Laubach et al., 2016;
Cornell and Kassim, 2016; Moreau et al., 2013). Patients should not be
deﬁned by one single characteristic: multiple factors should be con-
sidered in order to tailor treatment to the individual needs of each
patient. Here we provide an overview of the diﬀerent classes of agent
currently approved for the treatment of RRMM and the factors that
should guide treatment decisions. We also discuss additional con-
siderations for treating elderly patients, those with high-risk cytoge-
netic abnormalities and those with refractory disease.
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2. Classes of approved agent
2.1. Immunomodulatory drugs
The IMiD thalidomide, a synthetic derivative of glutamic acid, was
the ﬁrst immunomodulatory agent to be used for the treatment of MM
(Celgene Corporation Thalomid, 2014; Celgene Europe Ltd., 2016c;
Quach et al., 2010). The second-generation IMiDs lenalidomide and
pomalidomide are thalidomide analogues (Quach et al., 2010). IMiDs
possess multiple anti-myeloma properties that include immune mod-
ulation, along with anti-angiogenic, anti-inﬂammatory and anti-pro-
liferative eﬀects, which are mediated through direct and indirect me-
chanisms (Quach et al., 2010; Zhu et al., 2013). A direct anti-myeloma
mechanism of IMiDs was recently determined with the identiﬁcation of
the IMiD target cereblon, an adaptor subunit of the E3 ubiquitin ligase
that is required for their anti-myeloma activity. The binding of an IMiD
to cereblon alters its substrate speciﬁcity, resulting in aberrant pro-
teasomal degradation of the transcription factors Ikaros and Aiolos; this
leads to downregulation of the pro-myeloma interferon regulatory
factor 4 (Fig. 1). Lenalidomide, but not thalidomide or pomalidomide,
has also been shown to cause cereblon-mediated degradation of casein
kinase 1α, which leads to p53 activation (Ito and Handa, 2016). In-
direct mechanisms of IMiDs include immunomodulation mediated
through enhancement of CD4+ and CD8+ T cell co-stimulation,
downregulation of inﬂammatory cytokines and augmentation of anti-
myeloma natural killer cell activity (Zhu et al., 2013). Lenalidomide
and pomalidomide additionally inhibit regulatory T cells (Zhu et al.,
2013). Lenalidomide and pomalidomide are approved in the USA and
Europe for the treatment of patients with RRMM (Table 1).
2.2. Proteasome inhibitors
The PIs bortezomib, carﬁlzomib and ixazomib target the ubiqui-
tin–proteasome system, which is responsible for the degradation of
intracellular proteins and the maintenance of cellular protein home-
ostasis. Inhibition of this system aﬀects a number of components in cell-
signalling pathways, leading to cell-cycle arrest, promotion of apoptosis
and disruption of the stress response (Shah and Orlowski, 2009)
(Fig. 1). MM cells are particularly sensitive to proteasome inhibition
because they produce large quantities of protein in the form of im-
munoglobulin chains, and are dependent on proteasome-controlled
signalling pathways for protein degradation (inhibition of which leads
to the toxic accumulation of aggregated proteins) (Shah and Orlowski,
2009). Targeting the immunoproteasome, the proteolytic activity of
which generates peptide substrates optimized for presentation on the
major histocompatibility complex (MHC) class I molecules, is also re-
levant in MM because expression of the immunoproteasome is elevated
in cells of haematopoietic origin (Kuhn and Orlowski, 2012). Inhibition
of the immunoproteasome reduces surface expression of host protein
fragments on MHC class I molecules, and thus may enhance natural
killer cell-mediated cytotoxicity (Altun et al., 2005). Data suggest that
the inhibition of both the constitutive proteasome and the im-
munoproteasome may be required for MM cell cytotoxicity (Kuhn and
Orlowski, 2012).
Fig.1. Summary of sub-cellaulr pathway-directed novel agents.
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Although the three PIs share a molecular target, they diﬀer in their
active moiety and their binding reversibility (Teicher and Tomaszewski,
2015; Oﬃdani et al., 2014). Bortezomib and ixazomib are reversible
boronic acid inhibitors of the chymotrypsin-like activity of the pro-
teasome (Teicher and Tomaszewski, 2015; Oﬃdani et al., 2014). Car-
ﬁlzomib is an irreversible tetrapeptide epoxyketone PI that, compared
with bortezomib, is more selective for the chymotrypsin-like activity of
the proteasome and shows less reactivity with other proteasome sub-
units (Teicher and Tomaszewski, 2015; Demo et al., 2007; Yang et al.,
2011). In contrast to bortezomib and carﬁlzomib, ixazomib has good
oral bioavailability and thus can be administered in capsule form
(Oﬃdani et al., 2014). The European and American approvals for each
PI are detailed in Table 1.
2.3. Histone deacetylase inhibitors
HDIs are a novel class of agent in MM. Histone acetyltransferases
and HDACs are enzymes that control the acetylation status of proteins
and aﬀect a broad array of physiological processes, including cell-cycle
regulation, apoptosis and protein folding (Kaufman et al., 2013). In
MM, the inhibition of histone deacetylation leads to DNA damage and
upregulates proteins that promote apoptosis and cell-cycle arrest
(Moore, 2016). Panobinostat is the only HDI approved for the treatment
of RRMM; it is indicated in combination with bortezomib and dex-
amethasone in patients who have received at least two previous lines of
therapy including bortezomib and an IMiD (Table 1) (Farydak, 2016a;
Farydak, 2016b).
2.4. Monoclonal antibodies
mAbs targeted against antigens expressed on MM cells are an im-
portant new class of agent in MM treatment. Such mAbs induce cell
death via a number of mechanisms, including Fc-dependent eﬀector
mechanisms (antibody-dependent cell-mediated cytotoxicity, [ADCC]
complement-dependent cytotoxicity [CDC], and antibody-dependent
cellular phagocytosis [ADCP]) (Fig. 1). They may also have direct ef-
fects via modulation of the activity of the targeted antigen (van de Donk
et al., 2016).
Daratumumab is a fully human immunoglobulin G1 mAb against
CD38, a transmembrane glycoprotein that is highly expressed on MM
cells (van de Donk et al., 2016). Daratumumab kills MM cells via CDC,
ADCC, ADCP, direct induction of apoptosis, and modulation of CD38
ectoenzyme function (van de Donk et al., 2016). Daratumumab is in-
dicated as a single agent (Darzalex, 2015; Darzalex, 2016). In the USA,
daratumumab is also indicated in combination with lenalidomide plus
dexamethasone and with bortezomib plus dexamethasone (Darzalex,
2015). These combinations have recently received a positive opinion by
the European Committee for Medicinal Products for Human Use
(European Medicines Agency, 2017).
Elotuzumab is a humanized immunoglobulin G1 mAb against the
signalling lymphocytic activation molecule F7 (SLAMF7), a cell-surface
glycoprotein expressed on MM cells, natural killer cells and a subgroup
of other immune cells (van de Donk et al., 2016). Elotuzumab directly
enhances natural killer cell cytotoxicity via SLAMF7 ligation (van de
Donk et al., 2016). Elotuzumab is approved for use in combination with
lenalidomide and dexamethasone (Table 1) (Squibb, 2015; Squibb,
2016).
An overview of the mechanism of action of each class of agent is
presented in Fig. 1.
3. Treatment options for relapsed disease
The choice of therapy at relapse depends on a number of factors,
including eﬃcacy of and tolerance to previous therapy, number of
previous treatment lines, time since relapse and aggressiveness of re-
lapse, patient age, comorbidities and performance status (Cornell and
Kassim, 2016; Moreau et al., 2013). Data suggest that, for patients who
relapse following a durable response oﬀ treatment of at least 6–9
months, retreatment with the same or similar agents used in the pre-
vious line of therapy, or in combination with other agents, may induce
a second remission; in two retrospective studies of MM treatment pat-
terns, median time to progression was 9.3–9.7 months following re-
treatment with bortezomib (Conner et al., 2008; Hrusovsky et al.,
2010). However, in those who have experienced a short remission, re-
exposure to the same agent in sequential lines of therapy may be as-
sociated with increased rates of treatment resistance (Bird et al., 2014).
A second auto stem-cell transplantation (auto-SCT) may be con-
sidered in eligible patients who have previously received a transplant;
the results of several studies suggest that a minimum interval of 18
months from ﬁrst auto-SCT to relapse results in a second progression-
free survival (PFS) of approximately half the duration of the ﬁrst re-
mission (Laubach et al., 2016). In a recent study of 297 patients who
had relapsed following an auto-SCT, a second salvage auto-SCT resulted
in improved PFS compared with the control arm (19 months vs. 11
months) (Cook et al., 2016). The control arm in this study was cyclo-
phosphamide. The eﬃcacy of salvage auto-SCT compared with novel
targeted therapies is yet to be determined.
Drug therapies at relapse frequently incorporate an IMiD or a PI in
combination with dexamethasone. Results from phase III trials show
that, when used in combination with dexamethasone, IMiDs are asso-
ciated with signiﬁcant improvements in overall response rate (ORR)
and overall survival (OS) compared with dexamethasone alone
(Table 2) (Dimopoulos et al., 2007; Weber et al., 2007; San Miguel
et al., 2013; Dimopoulos et al., 2004; Dimopoulos et al., 2001; Kropﬀ
et al., 2012). IMiDs are associated with a number of adverse events
(AEs), notably haematological toxicity (including neutropenia and
thrombocytopenia) and venous thromboembolism (Table 2)
(Dimopoulos et al., 2007; Weber et al., 2007; San Miguel et al., 2013;
Dimopoulos et al., 2009). Thalidomide is additionally associated with
an increased risk of peripheral neuropathy (PN) (Rajkumar et al.,
2008). The PIs bortezomib and carﬁlzomib have been shown to im-
prove ORR and PFS when used in combination with dexamethasone
(Dimopoulos et al., 2016a; Harrison et al., 2015). Carﬁlzomib plus
dexamethasone has been shown to signiﬁcantly improve PFS and OS
compared with bortezomib plus dexamethasone in the head-to-head
phase III ENDEAVOR study (Table 2) (Dimopoulos et al., 2016a;
Dimopoulos et al., 2017). Currently there are no phase III study data
assessing ixazomib in combination with dexamethasone alone. AEs of
special interest that are associated with PIs include neutropenia,
thrombocytopenia, PN and cardiovascular events (Kyprolis, 2015;
Kyprolis, 2016; Velcade, 2016; Millennium Pharmaceuticals Velcade,
2015). In ENDEAVOR, carﬁlzomib was associated with a signiﬁcantly
lower incidence of PN of grade ≥2 than bortezomib (6% vs. 32%)
(Dimopoulos et al., 2016a). Although monotherapy is not commonly
used in patients with RRMM, it should be noted that bortezomib
monotherapy has shown eﬃcacy in the phase III APEX study (Table II)
(Harrison et al., 2015; Richardson et al., 2005). However, carﬁlzomib
monotherapy did not improve OS when compared with low-dose cor-
ticosteroid treatment (plus optional cyclophosphamide) in patients who
had received ≥3 previous lines of therapy (Table 2) (Hajek et al.,
2016). Currently there are no phase III trial data assessing the eﬃcacy
of ixazomib monotherapy. It should also be highlighted that the re-
cently approved mAb daratumumab has shown eﬃcacy as mono-
therapy in patients with RRMM who have received a minimum of three
previous lines of therapy or who had disease that was double refractory
to IMiDs and PIs in the phase II SIRIUS study (Table 2) (Lonial et al.,
2016).
Additionally, several studies have demonstrated increased eﬃcacy
when diﬀerent drug classes with distinct mechanisms of action are
combined for the treatment of RRMM, and recent guidelines re-
commend combination therapies in this setting (Laubach et al., 2016).
Doublet and triplet regimens often improve response rates compared
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with single-agent therapy, but they can be associated with increased
toxicity; therefore, single-agent or doublet therapy, rather than triplet
therapy, may be preferable in patients with a poor performance status
(Bird et al., 2014). With multiple classes of agent available, and now
often several drug options within each class, it can be a challenge for
the physician to determine which agent or combination of agents to use
at relapse (Fig. 2).
3.1. Combining IMiDs and PIs
Preclinical and clinical data in patients with RRMM provide strong
evidence for combining IMiDs and PIs. By targeting the im-
munoproteasome, PIs reduce expression of host protein fragments on
MHC class I molecules, enhancing natural killer cell-mediated cyto-
toxicity (Altun et al., 2005). Given the ability of IMiDs to stimulate
natural killer cells, a synergistic eﬀect is observed when these two
classes of agent are combined (Anderson, 2012). IMiDs and PIs may,
theoretically, work antagonistically because PIs could prevent de-
gradation of cereblon protein targets required for IMiD anti-myeloma
activity (Shi et al., 2015). However, in a phase III study in which pa-
tients received thalidomide and dexamethasone with or without bor-
tezomib, median PFS was signiﬁcantly longer for patients who received
bortezomib than those who did not (18.3 months vs. 13.6 months;
hazard ratio [HR], 0.59; P < 0.001) (Garderet et al., 2012). Grade 3
PN was, however, more frequent with the three-drug than with the two-
drug regimen (29% vs. 12%; P < 0.001) (Garderet et al., 2012). This is
perhaps unsurprising given that both thalidomide and bortezomib are
independently associated with an increased risk of PN (Rajkumar et al.,
2008; Richardson et al., 2005). In this study bortezomib was adminis-
tered intravenously on a twice-weekly dosing schedule (Garderet et al.,
2012). Subcutaneous administration of bortezomib on a weekly dosing
schedule rather than intravenous administration has been shown to
reduce the incidence of PN (Moreau et al., 2011; Mateos and San
Miguel, 2012). There was no diﬀerence in the incidence of cardiac AEs
between patients who received bortezomib and those who did not (15%
vs. 13%) (Richardson et al., 2005). However, bortezomib treatment has
been associated with cases of congestive heart failure or new-onset left
ventricular ejection fraction (Velcade, 2016).
In the phase III ASPIRE study, the addition of carﬁlzomib to lena-
lidomide and dexamethasone signiﬁcantly improved median PFS com-
pared with lenalidomide and dexamethasone (26.3 months vs. 17.6
months; P= 0.0001) in patients who had received one to three pre-
vious lines of therapy and whose disease had not progressed during
treatment with bortezomib or lenalidomide plus dexamethasone if it
was their most recent treatment (Table 2) (Stewart et al., 2015). In-
terestingly, patients in the carﬁlzomib group reported superior health-
related quality of life than those in the control group (Stewart et al.,
2015). Grade ≥3 AEs were reported in 83.7% of patients in the car-
ﬁlzomib group and 80.7% of patients receiving lenalidomide and dex-
amethasone only (Stewart et al., 2015). Cardiac AEs of grade ≥3 were
more common in the carﬁlzomib group than in the control group (hy-
pertension 4.3% vs. 1.8%; cardiac failure 3.8% vs. 1.8%; ischaemic
heart failure 3.3% vs. 2.1%, respectively). In contrast to the data pre-
sented above on combining bortezomib and IMiDs, adding carﬁlzomib
to lenalidomide and dexamethasone did not increase the incidence of
PN (17.1% vs. 17.0%, respectively) (Stewart et al., 2015).
The phase III TOURMALINE-MM1 study comparing ixazomib plus
lenalidomide and dexamethasone vs. lenalidomide and dexamethasone
provided further support for the combination of IMiDs and PIs in pa-
tients with RRMM (Table 2). The study enrolled patients who had re-
ceived one to three previous lines of therapy and who were not re-
fractory to previous therapy with lenalidomide or a PI. Median PFS was
signiﬁcantly longer for patients in the ixazomib group than for patients
receiving lenalidomide and dexamethasone only (20.6 months vs. 14.7
months; HR, 0.74; P= 0.01) (Moreau et al., 2016a). However, an up-
dated analysis conducted by the U.S. Food and Drug AdministrationTa
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found that ixazomib did not signiﬁcantly improve PFS compared with
control treatment (20.0 months vs. 15.9 months; HR, 0.82; P= 0.0548)
(Food and Drug Administration, 2015). Median OS has not been
reached in either group and the study is ongoing. The incidence of
grade 3 PN was 2% in both groups (Moreau et al., 2016a). Thrombo-
cytopenia of grade 3–4 occurred more frequently in the ixazomib group
(19%) than in the control group (9%). Additionally, compared with
control treatment, ixazomib was associated with an increased frequency
of low grade gastrointestinal AEs including diarrhoea (6% vs. 3%). This
is most likely because of its oral route of administration (Moreau et al.,
2016a).
Pomalidomide is indicated in patients who have received at least
two previous therapies including bortezomib and lenalidomide
(Table 1) (Celgene Corporation POMALYST, 2016; Celgene Europe Ltd.,
2016a) and is thus a treatment option at second or later relapse. New
triplet combinations based on the addition of a PI to pomalidomide plus
dexamethasone have shown promising eﬃcacy in phase I/II studies
(Hofmeister et al., 2013; Shah et al., 2015; Voorhees et al., 2015);
however, to date, no phase III trial data are available for these com-
binations.
3.2. Combining IMiDs and mAbs
Preclinical evidence shows that lenalidomide enhances the anti-
myeloma activity of elotuzumab and daratumumab via activation of the
eﬀector cells of ADCC (van de Donk et al., 2016). Recent clinical studies
support the use of this combination in patients with RRMM. In the
phase III ELOQUENT-2 trial, the addition of elotuzumab to lenalido-
mide and dexamethasone signiﬁcantly increased PFS compared with
lenalidomide and dexamethasone alone (19.4 months vs. 14.9 months;
P= 0.001) (Lonial et al., 2015a). Grade 3–4 lymphocytopenia occurred
more frequently in patients receiving elotuzumab than in the control
group (77% vs. 49%) (Table 2). Infusion reactions occurred in 10% of
patients in the elotuzumab group: most were grade 1 or 2 (Lonial et al.,
2015a). Elotuzumab has also been associated with secondary primary
malignancies (SPMs); 6.9% of patients receiving elotuzumab plus
lenalidomide and dexamethasone developed invasive SPMs compared
with 4.1% of patients receiving lenalidomide and dexamethasone
(Squibb, 2016). It must be noted that lenalidomide has also been as-
sociated with an increased risk of SPM. Overall, the incidence of SPMs
is low and should be considered in the context of the beneﬁts and risks
of treatment with other options (Musto et al., 2016).
In the phase III POLLUX study, the addition of daratumumab to
lenalidomide and dexamethasone signiﬁcantly increased PFS (not
reached [NR] vs. 18.4 months; HR, 0.37; P < 0.001) (Dimopoulos
et al., 2016b). Grade 3–4 AEs in the daratumumab and control groups
included neutropenia, thrombocytopenia and anaemia (Table 2). Infu-
sion reactions occurred in 48% of patients in the daratumumab group
and were mostly grade 1 or 2 (Dimopoulos et al., 2016b). Infusion re-
actions are a key safety signal for both elotuzumab and daratumumab,
with most AEs of this type occurring during the ﬁrst infusion (Squibb,
2016; Darzalex, 2016). The incidence and severity of infusion reactions
can be reduced by the pre-infusion prophylactic administration of
dexamethasone, antihistamines and acetaminophen (van de Donk et al.,
2016).
Although mature phase III study data are available only for lenali-
domide and mAbs, preclinical and clinical synergy has also been de-
monstrated between mAbs and the IMiDs thalidomide and pomalido-
mide; phase II and III studies assessing these combinations are ongoing
(Chari et al., 2015; Mateos et al., 2016a; San Miguel et al., 2016).
3.3. Combining PIs and mAbs
Preclinical data show enhanced ADCC in MM cells when bortezomib
and daratumumab are used together. The synergistic eﬃcacy of these
two classes of agent has been conﬁrmed in the phase III CASTOR study
comparing daratumumab plus bortezomib and dexamethasone vs.
bortezomib and dexamethasone. In a pre-speciﬁed interim analysis,
treatment with daratumumab led to a signiﬁcant increase in median
PFS compared with bortezomib and dexamethasone treatment alone
(NR vs. 7.2 months; HR, 0.39; P < 0.001) (Palumbo et al., 2016).
Grade 3–4 AEs in the daratumumab group and the bortezomib and
Fig. 2. Proposed treatment pathway for the man-
agement of RRMM.
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dexamethasone only group included thrombocytopenia, anaemia and
neutropenia (Table 1). Infusion-related reactions were reported in
45.3% of the patients in the daratumumab group; these reactions were
mostly grade 1–2 (Palumbo et al., 2016). As noted above, most infusion
reactions associated with mAbs occur during the ﬁrst dose (Darzalex,
2016). It should also be noted that daratumumab treatment has been
shown to interfere with blood compatibility testing, which may com-
plicate blood transfusions (Dimopoulos et al., 2016b).
No phase III study data are available on the combination of mAbs
with carﬁlzomib or ixazomib, but it is possible that similar synergy
would be seen with these PIs.
3.4. Combining PIs and HDIs
By inhibiting the proteasome, PIs lead to accumulation of protein
aggregates that can be removed from the cell by autophagy. HDAC6 is
thought to promote MM cell survival by facilitating autophagy, and
HDIs prevent HDAC6 from performing this function. Therefore, a sy-
nergistic eﬀect is seen when combining PIs and HDIs (Kaufman et al.,
2013). In the phase III PANORAMA 1 study, addition of panobinostat to
bortezomib and dexamethasone signiﬁcantly improved PFS compared
with bortezomib and dexamethasone alone (12.0 months vs. 8.1
months; HR, 0.63: P < 0.0001). There was no signiﬁcant diﬀerence in
median OS between the panobinostat and control groups; however, OS
data are not mature and the study is ongoing (San-Miguel et al., 2014).
Grade 3–4 AEs that occurred more frequently in the panobinostat plus
bortezomib and dexamethasone group than in the bortezomib and
dexamethasone group were diarrhoea (25.5% vs. 8.0%), nausea (5.5%
vs. < 1.0%) and vomiting (7.3% vs. 1.3%) (Table 2) (San-Miguel et al.,
2014).
4. Special patient subgroups
With the expanding treatment options now available in RRMM, the
individualization of treatment is becoming increasingly important to
optimize patient outcomes. Better understanding of treatment eﬀects in
patient subgroups can, therefore, help to inform physicians. Despite
many studies not being powered to analyse diﬀerential treatment out-
comes between patient subgroups, they can provide helpful information
to aid treatment pathway decisions. However, it is important to note
that although subgroup data are useful, patients may have multiple
subgroup characteristics and thus treatment selection should be guided
by multiple patient and disease factors. Subgroup analyses from pivotal
studies in RRMM are presented in Table 3.
4.1. Elderly patients
Management of RRMM in elderly patients (those aged ≥65 years)
and very elderly patients (those aged ≥75 years) is particularly chal-
lenging owing to an increased burden of patient comorbidities and a
reduced resilience to treatment-related toxicities (Larocca and
Palumbo, 2015). A meta-analysis of 1435 patients aged≥65 years who
were enrolled in four phase III studies conﬁrmed that an age of ≥75
years is an independent negative risk factor for death (Bringhen et al.,
2013). The survival beneﬁts seen in younger patients following the
availability of novel agents have not been observed to the same extent
in elderly patients (Schaapveld et al., 2010). In very elderly frail pa-
tients, the aim of treatment may not be to achieve a deep response but
rather to maintain the disease in an asymptomatic state in order to
preserve quality of life while avoiding excessive toxicity (Larocca and
Palumbo, 2015).
Elderly patients comprise a heterogeneous population of variable
ﬁtness, so the decision regarding when and how intensely to treat de-
pends upon the characteristics of the patient (Kastritis et al., 2015).
When making treatment decisions in this patient population, there is
clear beneﬁt in the use of geriatric assessment scores that combine
multiple patient factors including age, comorbidity burden and func-
tional status (Palumbo et al., 2015a; Hamaker et al., 2012). Indeed, in a
recent pooled analysis of 869 elderly patients, scoring individuals for
ﬁtness according to age, comorbidities and cognitive and physical
condition predicted mortality and risk of toxicity (Palumbo et al.,
2015a). Several studies of novel classes of agent in RRMM, including
IMiDs, PIs and mAbs, have reported similar eﬃcacy in elderly patients
compared with younger patients (San Miguel et al., 2013; Lonial et al.,
2016; Lonial et al., 2015a; Castelli et al., 2015; Palumbo et al., 2014;
Palumbo et al., 2015c). However, currently, no data are available on
the eﬃcacy of diﬀerent treatment regimens according to the geriatric
score, and subgroup analyses according to age have been conducted by
chronological age only. Additionally, frailty scores are time consuming
to calculate and thus are rarely used in routine clinical practice; the
development of computer-based applications to calculate frailty scores
may help to increase their use (Palumbo et al., 2015a).
Clinical data show that the IMiDs and PIs have eﬃcacy in elderly
patients (San Miguel et al., 2013; Palumbo et al., 2014; Richardson
et al., 2007; Touzeau et al., 2012). In the MM-003 pomalidomide study,
the HR for death or disease progression with pomalidomide plus dex-
amethasone vs. dexamethasone alone was 0.50 for patients aged ≤75
years and 0.36 for patients aged>75 years (San Miguel et al., 2013). In
the ENDEAVOR study carﬁlzomib showed improved PFS compared
with bortezomib, when both PIs were used in combination with dex-
amethasone (Dimopoulos et al., 2016a). Median PFS was improved in
each age subgroup receiving carﬁlzomib compared with bortezomib
( < 65 years: NR vs. 9.5 months; 65–74 years: 15.6 months vs. 9.5
months; ≥75 years: 18.7 months vs. 8.9 months) (Palumbo et al.,
2015c). Carﬁlzomib also improved OS for each age subgroup compared
with bortezomib (HR for death, < 65 years: 0.85; 65–74 years: 0.71;
≥75 years: 0.84) (Dimopoulos et al., 2017). However, improvements in
PFS and OS reported for patients aged ≥75 should be interpreted
carefully owing to relatively small patient numbers in these analyses;
77 and 66 patients were aged ≥75 years in the carﬁlzomib and bor-
tezomib groups, respectively.
Combination therapy with IMiDs and PIs have also shown eﬃcacy
in elderly patients. In the ASPIRE study, addition of carﬁlzomib to le-
nalidomide and dexamethasone resulted in improved outcomes for el-
derly patients compared with control treatment; however, the clinical
beneﬁt was not as great as that seen for younger patients (HR for dis-
ease progression with carﬁlzomib,≥65 years: 0.85; 18–64 years, 0.60)
(Stewart et al., 2015). Interim analysis of the TOURMALINE-MM1 study
showed that addition of ixazomib to lenalidomide and dexamethasone
improved median PFS for patients aged ≤65 years and for those aged
≥75 years, but not for patients aged> 65–75 years (≤65 years: 20.6
months vs. 14.1 months;> 65–75 years: 17.5 months vs. 17.6 months;
≥75 years: 18.5 months vs. 13.1 months) (Moreau et al., 2016a).
However, owing to relatively small patient numbers in these subgroup
analyses (47 and 61 patients were aged>75 years in the ixazomib and
placebo groups, respectively), further studies will be needed to clarify
the role of ixazomib in patients aged 65–75 years. Ixazomib may be a
good option for very elderly patients because of its weekly oral ad-
ministration and its tolerable safety proﬁle (discussed above and pre-
sented in Table 2) (Larocca and Palumbo, 2015).
The HDI panobinostat in combination with the PI bortezomib and
dexamethasone provided improved outcomes in elderly patients com-
pared with bortezomib and dexamethasone alone, although the impact
was not as great as that seen in younger patients (HR, ≥65 years:
0.72;< 65 years: 0.59) (San-Miguel et al., 2014).
Newly approved mAbs, in combination with either an IMiD or a PI,
have been shown to give striking improvements in outcomes for elderly
patients with RRMM. Elotuzumab in combination with lenalidomide
and dexamethasone improved PFS in older patients compared with le-
nalidomide and dexamethasone alone (HR, ≥65 years:
0.65;< 65 years: 0.75) (Lonial et al., 2015a). Similarly, daratumumab
in combination with bortezomib and dexamethasone signiﬁcantly
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increased PFS for elderly patients compared with bortezomib and
dexamethasone alone (HR, ≥65 years: 0.35;< 65 years: 0.44)
(Palumbo et al., 2016). Daratumumab monotherapy may also be a good
treatment option for elderly patients with RRMM; in the SIRIUS study,
the ORR with daratumumab was 31.0% in patients aged 18–64 years,
25.0% in those aged 65–74 years and 33.3% for those aged ≥75 years
(Lonial et al., 2016).
Elderly patients are more susceptible to AEs than younger patients
(Larocca and Palumbo, 2015), and bortezomib-induced thrombocyto-
penia and lenalidomide-induced myelosuppression are a concern in
these patients (Mehta et al., 2010; Tosi et al., 2013). Platelet transfusion
should be considered for the treatment of thrombocytopenia (Velcade,
2016), and antibacterial prophylaxis may be warranted in severe cases
of myelosuppression (Larocca and Palumbo, 2015). Subgroup analyses
of the ENDEAVOR study showed that cardiac AEs associated with car-
ﬁlzomib occurred most frequently in very elderly patients (Palumbo
et al., 2015c). Elderly patients should be monitored for AEs more fre-
quently than younger patients to ensure that AEs, where possible, are
treated and/or doses reduced to ensure treatment can be continued
(Table 4). However, in the ENDEAVOR study, the greatly improved
eﬃcacy of carﬁlzomib compared with bortezomib in very elderly pa-
tients may relate to better overall tolerability of carﬁlzomib. Rates of
discontinuation owing to AEs between the two treatment arms were
similar in patients aged<65 years and those aged 65–74 years; how-
ever, in patients aged ≥75 years, discontinuations were higher in the
bortezomib arm than in the carﬁlzomib arm (35% vs. 26%) (Palumbo
et al., 2015c). Carﬁlzomib may, therefore, be an attractive option for
elderly patients who could beneﬁt from treatment with a PI. Reduction
in bortezomib treatment frequency is eﬃcacious and may help to re-
duce the AEs associated with this therapy (Ozaki et al., 2016;
Fukushima et al., 2011).
4.2. Patients with high-risk cytogenetic abnormalities
MM is a highly heterogeneous disease both phenotypically and
genotypically (Chng et al., 2014). A number of genetic abnormalities
have been associated with poor prognosis, including del(17p), t(4;14), t
(14;16) and gain in 1q (Moreau et al., 2014; Mikhael et al., 2013). Until
recently, risk classiﬁcation did not impact on treatment decisions.
However, data show that, compared with two-drug combinations,
three-drug combinations improve outcomes for patients with high-risk
cytogenetic abnormalities (CAs) (Stewart et al., 2015; Moreau et al.,
2016a; Lonial et al., 2015a; Dimopoulos et al., 2010). For patients with
high-risk CAs, aggressive therapy should be used to prevent the emer-
gence of resistant clones. This approach may require treatment gaps or
shorter treatment durations compared with less aggressive therapy
(Lonial et al., 2015b).
When considering data on treatment eﬃcacy in patients with high-
risk CAs, it is important to note that deﬁnitions of high-risk CAs may
diﬀer between studies. A consensus on the standardization of analytical
techniques and the proportion of abnormal cells that determine high-
risk disease is needed (Sonneveld et al., 2016). Despite this, the iden-
tiﬁcation of patients who have high-risk CAs is now a crucial ﬁrst step
in managing their disease. CAs may diﬀer between ﬁrst and later
Table 4
Safety considerations for elderly patients (Farydak, 2016b; Squibb, 2016; Darzalex, 2016; Celgene Europe Ltd., 2016a; Celgene Europe Ltd., 2016b; Kyprolis, 2016; Millennium
Pharmaceuticals Ninlaro, 2015; Celgene Europe Ltd., 2016c; Velcade, 2016).
Agent Special considerations for elderly patients Dose reductions
Immunomodulatory drugs
Thalidomide No overall diﬀerence in safety was observed between patients aged>75 years
and younger patients; however, patients aged> 75 years are potentially at risk
of a higher frequency of serious AEs
No speciﬁc dose adjustments are recommended for patients
aged ≤75 years
For patients aged> 75 years, the recommended starting dose
is 100 mg/day
Lenalidomide No overall diﬀerence in safety was observed between elderly and younger
patients, but a greater predisposition of older individuals to AEs cannot be ruled
out
Initial dose: 25 mg/day
Myelosuppression is a concern in elderly patients First reduction: 15 mg/day
Elderly patients are more likely to have decreased renal function; therefore, care
should be taken in dose selection and renal function should be monitored
Second reduction: 10 mg/day
Third reduction: 5 mg/day
Pomalidomide No dose adjustment is required for patients aged ≥65 years
Proteasome inhibitors
Bortezomib Thrombocytopenia is a particular concern for elderly patients No dose adjustment is required for patients aged ≥65 years
Carﬁlzomib The subject incidence of AEs (including cardiac failure) was higher for patients
aged ≥75 years compared with patients aged< 75 years
Carﬁlzomib, lenalidomide and dexamethasone
Initial dose: 27 mg/m2
First reduction: 20 mg/m2
Second reduction: 15 mg/m2
Carﬁlzomib and dexamethasone
Initial dose: 56 mg/m2
First reduction: 45 mg/m2
Second reduction: 36 mg/m2
Third reduction: 27 mg/m2
Ixazomib No overall diﬀerences in safety were observed between elderly patients and
younger patients, but greater sensitivity of some older individuals cannot be
excluded
Histone deacetylase inhibitors
Panobinostat It is recommended to monitor patients aged ≥65 years more frequently,
especially for thrombocytopenia and gastrointestinal toxicity
Panobinostat treatment may be started at a dose of 15 mg, and
if tolerated in the ﬁrst cycle, escalated to 20 mg in the second
cycle
For patients aged>75 years, dose adjustments may be considered
Monoclonal antibodies
Daratumumab No dose adjustment is required for patients aged ≥65 years
Elotuzumab No dose adjustment is required for patients aged ≥65 years
AE, adverse event.
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relapses because of clonal evolution, which may inﬂuence the eﬀect of
treatment (Sonneveld et al., 2016). Currently, however, many patients
are not tested for CAs and, furthermore, retesting at relapse is not
routinely performed. Owing to the impact of high-risk CAs on treatment
decisions, it is recommended that patients with a normal cytogenetic
proﬁle at diagnosis should be retested at relapse.
Data are conﬂicting on the use of IMiDs in patients with high-risk
CAs: eﬃcacy appears to be aﬀected by the speciﬁc genetic mutation
present. Thalidomide is not recommended for patients with high-risk
CAs (Lonial et al., 2015b); the role of other IMiDs in high-risk disease is
unclear. A subgroup analysis of the MM016 trial compared lenalido-
mide plus dexamethasone with dexamethasone alone in 130 patients
with del(13q), t(4;14) or del(17p13) (Reece et al., 2009). Compared
with patients without high-risk CAs, median OS was similar for patients
with del(13q) (24.5 months vs. 14.7 months; P= 0.15) or t(4;14) (18.1
months vs. 23.7 months; P= 0.91) (Reece et al., 2009). However,
compared with patients without high-risk CAs, those with del(17p13)
had a signiﬁcantly worse outcome (median OS, 23.7 months vs. 4.7
months; P= 0.001) (Reece et al., 2009). Pomalidomide, in combina-
tion with dexamethasone, has shown eﬃcacy in the treatment of pa-
tients with high-risk CAs (San Miguel et al., 2013). Results from the
Intergroupe Francophone Myélome (IFM) 2010–02 trial showed that
patients with del(17p) gained beneﬁt from treatment with pomalido-
mide and dexamethasone, whereas patients with t(4;14) did not gain
beneﬁt from this combination (Leleu et al., 2015).
PIs have also shown some eﬃcacy in the treatment of patients with
high-risk CAs. A prospective study assessing the impact of cytogenetics
on treatment outcome with bortezomib in combination with lenalido-
mide and dexamethasone found that for patients receiving bortezomib,
there was no diﬀerence in ORR between those with high-risk CAs and
those with standard-risk cytogenetics (P= 0.219) (Dimopoulos et al.,
2010). However, in the control group (lenalidomide plus dex-
amethasone), the ORR was signiﬁcantly lower for patients with high-
risk CAs than for those with standard-risk cytogenetics (P= 0.01)
(Dimopoulos et al., 2010).
Carﬁlzomib may be a more potent PI option than bortezomib for
patients with high-risk CAs. In pre-planned subgroup analyses of
ENDEAVOR, carﬁlzomib improved outcomes compared with borte-
zomib regardless of cytogenetic risk category. Carﬁlzomib prolonged
PFS compared with bortezomib in patients with high-risk CAs (8.8
months vs. 6.0 months; HR, 0.65; P= 0.0075) and in those with
standard-risk cytogenetics (not estimable vs. 10.2 months; HR, 0.44;
P < 0.0001); however, it must be noted that outcomes for patients
with high-risk CAs were worse than for those with standard-risk CAs
(Chng et al., 2017). Carﬁlzomib has also shown eﬃcacy in this patient
population in combination with lenalidomide and dexamethasone. In
ASPIRE, a signiﬁcant increase in PFS was observed with carﬁlzomib
regardless of patients’ cytogenetic risk, where a 60% cut-oﬀ was used to
deﬁne high-risk patients for t(4;14), t(14;16) and del(17p). In patients
with high-risk CAs, there was a trend for increased PFS with carﬁlzomib
compared with lenalidomide and dexamethasone alone by 9 months
(P= 0.083) (vs. an increased PFS of 10 months for patients with
standard-risk cytogenetics; P= 0.003) (Avet-Loiseau et al., 2016).
However, it must be noted that in both ENDEAVOR and ASPIRE car-
ﬁlzomib treatment did not completely overcome the poor prognosis
associated with high-risk CAs (Stewart et al., 2015; Chng et al., 2017;
Avet-Loiseau et al., 2016).
In TOURMALINE-MM1, ixazomib in combination with lenalidomide
and dexamethasone has also been shown to improve outcomes for pa-
tients with high-risk CAs compared with lenalidomide and dex-
amethasone alone: in the primary analysis, median PFS among patients
with high-risk CAs was 21.4 months and 9.7 months, respectively. This
improvement in PFS was greater than that seen in patients with stan-
dard-risk cytogenetics (HR, 0.54 vs. 0.64) (Moreau et al., 2016a).
However, the false positive cut-oﬀs used to deﬁne patients with high-
risk CAs were 5%, 3% and 3% for del(17p), t(4;14) and t(14;16),
respectively, which diﬀered from cut-oﬀs used in similar trials of novel
agents (Stewart et al., 2015; Lonial et al., 2015a). Post hoc analyses
were conducted using more stringent cut-oﬀs for del(17p) (20% and
60%) and t(4;14) (10%), which showed that the beneﬁcial eﬀect of
ixazomib in patients with high-risk CAs was maintained regardless of
the false-positive cut-oﬀ used to deﬁne high-risk patients (Richardson
et al., 2016). It must be noted that the most appropriate cut-oﬀ for each
mutation type is not known. Serial analysis of bone marrow aspirates
from 936 patients by the IFM group showed that in relation to outcome
the most powerful cut-oﬀs were 74% for del(13) and 60% for del(17p)
(Avet-Loiseau et al., 2007). For interpretation of all of the above trials,
it must be noted that PFS is poor in patients with high-risk CAs treated
with lenalidomide and dexamethasone only, and this two-drug combi-
nation is not recommended in this patient population.
The mAbs daratumumab and elotuzumab are also good treatment
options for patients with high-risk CAs. In the ELOQUENT-2 study,
elotuzumab exhibited similar eﬃcacy across all patient subgroups, in-
cluding those with high-risk CAs: HRs for disease progression ranged
from 0.53 to 0.75 for patients with del(17p), 1q21 and t(4;14) com-
pared with 0.70 for the overall population. However, for del(17p) no
cut-oﬀ was used and patients were considered positive if one or more
cells had the del(17)p mutation; therefore, the results must be con-
sidered with caution (Lonial et al., 2015a). Similar results were found
for daratumumab monotherapy in the single-arm SIRIUS study: the
ORR was 20% in patients with high-risk CAs compared with 29.4% in
those with standard-risk cytogenetics (Lonial et al., 2016). The eﬃcacy
of daratumumab in patients with high-risk CAs was conﬁrmed in recent
subgroup analyses of the POLLUX and CASTOR trials. In patients who
had received one to three previous lines of therapy and had high-risk
CAs, the addition of daratumumab to lenalidomide and dexamethasone
signiﬁcantly improved PFS (NR vs. 8.3 months; HR, 0.30; P= 0.0019)
and ORR (91% vs. 69%; P= 0.0267) compared with lenalidomide and
dexamethasone treatment (Usmani et al., 2016a). In CASTOR, in pa-
tients who had received one to three previous lines of therapy and who
had high-risk CAs, the addition of daratumumab to bortezomib and
dexamethasone signiﬁcantly improved PFS (HR, 0.46; P= 0.0367) and
12-month PFS rates (63% vs. 27%) compared with bortezomib and
dexamethasone treatment (Mateos et al., 2016b). For comparison, the
12-month PFS rates for patients without high-risk CAs in this subgroup
analysis were 58% for daratumumab plus bortezomib and dex-
amethasone and 27% for bortezomib and dexamethasone (Mateos et al.,
2016b).
5. Patients with refractory disease: switching within and between
classes of agent
Owing to the relapsing disease course of MM, patients will often
receive multiple lines of therapy. Refractory disease is, therefore, a
major challenge in the treatment of relapsed MM. With most patients
receiving a backbone therapy of an IMiD and dexamethasone or a PI
and dexamethasone, the development of disease that is refractory to
one or both of these classes is a concern in RRMM. A key question
following the development of refractory disease is whether to switch
the class of agent from the previous line or to switch to another treat-
ment option within the same class of agent (Ludwig et al., 2014).
5.1. IMiD-refractory disease
Evidence suggests that switching to other agents within the IMiD
class can be eﬀective in IMiD-refractory disease. Pomalidomide has
shown eﬃcacy in patients who are refractory to lenalidomide. In the
MM-003 trial, pomalidomide improved outcomes compared with high-
dose dexamethasone regardless of lenalidomide-refractory status;
median PFS was signiﬁcantly longer with pomalidomide in patients
who were refractory to lenalidomide (3.9 months vs. 1.9 months;
P < 0.0001) (San Miguel et al., 2013). Additionally, in the single-arm
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phase IIIb STRATUS study of pomalidomide with low-dose dex-
amethasone, most enrolled patients were refractory to lenalidomide
(96%), bortezomib (84%) or both (80%). Subgroup analyses showed
that the eﬃcacy (ORR, OS and PFS) of pomalidomide in combination
with dexamethasone was independent of treatment history: ORRs were
generally similar regardless of previous thalidomide therapy, number of
previous regimens and resistance to lenalidomide or bortezomib
(Moreau et al., 2015).
Combining agents with synergistic activity may also overcome drug
resistance. In a recent phase I/II study in patients who had received
multiple previous lines of therapy, the addition of prednisone and low-
dose cyclophosphamide to lenalidomide led to an ORR of 67%, a
median PFS of 12.1 months and a median OS of 29.0 months.
Interestingly, similar results were achieved in the subset of patients
with lenalidomide-refractory disease, and in those with bortezomib-
refractory disease (Nijhof et al., 2016).
Switching to another class of agent may also overcome resistance to
IMiDs. In CASTOR, for patients with IMiD-refractory disease (32.3% of
the total patient population), median PFS was 9.2 months in those re-
ceiving daratumumab compared with 5.4 months in the control group
(Palumbo et al., 2016). Subgroup analysis showed that among patients
who were refractory to lenalidomide at the last previous treatment line,
PFS was signiﬁcantly longer with daratumumab than in the control
group (10.3 months vs. 4.4 months; HR, 0.37; P= 0.0004) (Chanan-
Khan et al., 2016). It must be noted, however, that eﬃcacy was greater
in patients without refractory disease than in those with refractory
disease (PFS with daratumumab was NR in the total population)
(Palumbo et al., 2016).
PIs have also shown eﬃcacy in patients with lenalidomide-re-
fractory disease. In ASPIRE, carﬁlzomib improved PFS compared with
lenalidomide and dexamethasone alone in patients who were refractory
to an immunomodulatory agent and in those who were not (HR, 0.64
and 0.72). These results should, however, be interpreted with caution
owing to the relatively small number of patients in this study who had
disease refractory to an immunomodulatory agent (85 patients re-
ceiving carﬁlzomib and 88 patients in the control group had im-
munomodulatory agent refractory disease). (Stewart et al., 2015). In
subgroup analyses of ENDEAVOR, for patients receiving carﬁlzomib
plus dexamethasone, median PFS was 8.6 months for patients with le-
nalidomide-refractory disease and not estimable in those who were not
refractory to lenalidomide. In individuals receiving bortezomib plus
dexamethasone, median PFS was 6.6 months for patients with lenali-
domide-refractory disease and 11.2 months for those who were not
refractory to lenalidomide (Moreau et al., 2016c). It must be noted that
for both PIs eﬃcacy was greater in patients who were not refractory to
lenalidomide than in those with refractory disease.
5.2. PI-refractory disease
The second-generation PI carﬁlzomib has shown eﬃcacy in patients
who are refractory to bortezomib. In a phase I/II trial, bortezomib was
replaced with carﬁlzomib in patients who had progressed while re-
ceiving or within 12 weeks of receiving a bortezomib-containing re-
gimen. The study found that the use of carﬁlzomib in patients who were
refractory to bortezomib was both eﬀective and had a good tolerability
proﬁle; median PFS was 8.3 months and median duration of response
was 9.9 months for patients who experienced a partial response or
better (Berenson et al., 2014). Very few patients who were refractory to
bortezomib were included in the ENDEAVOR study because patients
could be randomised to the bortezomib arm, making it diﬃcult to
analyse outcomes in this subgroup.
Adding a novel class of agent can also elicit a response in patients
with PI-refractory disease. Data from the PANORAMA 2 study found
that the addition of panobinostat elicited responses in patients with
RRMM who were previously refractory to bortezomib: the ORR was
34.5% and the median duration of response was 6.0 months
(Richardson et al., 2013).
Switching between agents is also an option for PI-refractory disease,
and the mAb daratumumab has shown eﬃcacy in this setting. In
POLLUX, 28% of patients receiving daratumumab and 27% of those
receiving lenalidomide plus dexamethasone alone were refractory to
the last line of previous therapy; 20% of patients receiving dar-
atumumab and 16% of those in the control group were PI refractory;
patients refractory to lenalidomide were excluded from the study. In the
total patient population, the ORR was 93% for patients receiving dar-
atumumab plus lenalidomide and dexamethasone compared with 76%
for patients receiving lenalidomide and dexamethasone alone.
Treatment with daratumumab resulted in a HR of 0.37 for the total
population and 0.50 for those refractory to a proteasome inhibitor for
PFS (Dimopoulos et al., 2016b). Subgroup analyses showed that among
patients who were refractory to bortezomib, PFS was signiﬁcantly
longer with daratumumab than in the control group (NR vs. 10.3
months; HR, 0.46; P= 0.0117) (Moreau et al., 2016b).
5.3. Double refractory disease
Patients with double refractory disease (those resistant to both
IMiDs and PIs) have very poor prognosis (median PFS and OS of 5
months and 9 months, respectively) (Kumar et al., 2012). Pomalido-
mide in combination with dexamethasone has shown limited eﬃcacy in
these patients. In individuals with disease refractory to lenalidomide
and bortezomib, treatment with pomalidomide led to an ORR of 31%,
median PFS of 3.8 months and median OS of 13.8 months (Leleu et al.,
2013). The novel combination of pomalidomide plus carﬁlzomib and
dexamethasone has also shown eﬃcacy in heavily pretreated patients.
The phase I dose-escalation study of this combination, in which all
patients were refractory to lenalidomide and most (91%) were also
refractory to bortezomib, reported an ORR of 50% and median OS of
20.6 months (Shah et al., 2015).
Mechanisms of resistance towards previous therapies do not appear
to aﬀect response to the mAbs, making these good treatment options for
patients with double refractory disease. In the SIRIUS study of 106
heavily pretreated patients (median of ﬁve previous lines), dar-
atumumab monotherapy resulted in a 29.2% ORR and an estimated 1-
year OS of 65% (Lonial et al., 2016). A partial response or better was
reported in 29.7% of patients who were refractory to an IMiD and a PI
(Lonial et al., 2016). The eﬃcacy of daratumumab in heavily pretreated
patients is additionally supported by a recent pooled analysis of 148
patients who took part in two phase II trials of daratumumab mono-
therapy (Usmani et al., 2016b). Among the pooled population, patients
had received a median of ﬁve previous lines of therapy, and 87% were
double refractory to an IMiD and a PI: the ORR was 31.1% and median
PFS and OS were 4.0 months and 20.1 months, respectively (Usmani
et al., 2016b). In the ELOQUENT-2 study, assessing the eﬃcacy of
combining elotuzumab with lenalidomide and dexamethasone, most
patients had previously received an IMiD (thalidomide or lenalidomide)
or a PI (bortezomib), and 35% of patients were resistant to their pre-
vious therapy (Lonial et al., 2015a). Compared with the control group,
the HR for disease progression with elotuzumab was 0.56 for patients
who were resistant to their previous therapy and 0.77 for those who
relapsed following response to their previous therapy (Lonial et al.,
2015a).
Overall, current data show that, for patients with single or double
refractory disease, switching agents within a class as well as between
classes can lead to clinical response in the relapsed setting.
6. Conclusions
The treatment options for patients with RRMM have expanded
dramatically in recent years, and now there are multiple new classes of
agent available. It is important that survival improvements aﬀorded by
the availability of new agents are extended to all patients including the
G. Cook et al. Critical Reviews in Oncology / Hematology 121 (2018) 74–89
86
elderly and those with high-risk CAs. There is a need for improved
diﬀerentiation of patients with RRMM, which should not be considered
a single disease but rather a mix of diﬀerent disease entities that further
interact with individual patient characteristics (Palumbo et al., 2015b).
Better understanding of the mechanism of action of each agent and its
clinical eﬃcacy in diﬀerent patient subgroups, and in patients with
characteristics that ﬁt within multiple subgroups, will enable physi-
cians to navigate the treatment landscape, leading to individualized
treatment and better patient outcomes.
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